Limitations in current clinical trials on renal denervation
Wang, Yutang (2014) Limitations in current clinical trials on renal denervation. International Journal of Cardiology, 174 (1). 225 -225.
|
PDF (Author Accepted Version)
- Accepted Version
Download (138kB) | Preview |
|
![[img]](https://researchonline.jcu.edu.au/style/images/fileicons/application_pdf.png) |
PDF (Published Version)
- Published Version
Restricted to Repository staff only |
Abstract
[Extract] Renal denervation (RDN) has become a standard treatment option to lower blood pressure (BP) in patients with resistant hypertension in many countries since 2010. There is a huge interest in investigating the effect of RDN on resistant hypertension and other diseases (e.g. diabetes and heart failure), and 118 clinical trials have been registered at ClinicalTrials.gov. A large number of early clinical trials demonstrate that RDN lowers blood pressure. However, on 9 January 2014, Medtronic reported that RDN did not lower blood pressure in the randomized and sham controlled Symplicity HTN-3 trial.
| Item ID: | 34890 |
|---|---|
| Item Type: | Article (Commentary) |
| ISSN: | 1874-1754 |
| Date Deposited: | 26 May 2015 03:58 |
| FoR Codes: | 11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiovascular Medicine and Haematology > 110201 Cardiology (incl Cardiovascular Diseases) @ 100% |
| SEO Codes: | 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920101 Blood Disorders @ 0% 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920102 Cancer and Related Disorders @ 0% 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100% |
| Downloads: |
Total: 1120 Last 12 Months: 6 |
| More Statistics |
Actions (Repository Staff Only)
 |
Item Control Page |